Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Life Sciences

GEN Publishes 2017 Top 10 U.S. Biopharma Clusters List; New Jersey/New York Ranked No. 3

New Rochelle, NY, August 26, 2017Genetic Engineering & Biotechnology News (GEN) on June 5 published its 2017 Top 10 US Biopharma Clusters list.  New Jersey/New York is number three on the list, the same position it was on GEN’s 2016 Top 10 list.

GEN’s Top 10 U.S. Biopharma Clusters are:

  1. Boston-Cambridge
  2. San Francisco Bay Area
  3. New Jersey/New York
  4. San Diego
  5. Maryland, Virginia and DC Metro
  6. San Diego
  7. Greater Philadelphia
  8. Seattle
  9. Raleigh/Durham (includes Research Triangle Park)
  10. Los Angeles/Orange County
  11. Chicagoland

Continue reading

Choose New Jersey CEO Michele Brown: ‘Access to Lab Space, Funding and Partners Help Biotech Companies Grow in Garden State’

Michele Brown (Photo: NJBIZ/Aaron Houston)

Trenton, NJ, August 1, 2017Choose New Jersey, Inc. led a delegation representing more than 20 New Jersey organizations — including top life sciences companies, universities, trade associations, state officials — as it showcased New Jersey’s assets and resources for biotechnology companies at BIO International 2017, which was June 19-22 in San Diego, California. 

Prior to the BIO event, Choose New Jersey President and Chief Executive Officer Michele Brown in June wrote:

When Hurel Corporation outgrew its incubator space at the Commercialization Center for Innovative Technologies (CCIT) in North Brunswick, New Jersey in 2016, it marked an important milestone for the biotechnology company. Continue reading

EVENT: Save the Date! HINJ to Host 2017 Life Sciences Celebration on October 12 in Trenton

New Brunswick, NJ, July 31, 2017 ― Please mark your calendar to join the HealthCare Institute of New Jersey (HINJ) in honoring meritorious leadership in and contributions to New Jersey’s life sciences community at HINJ’s Life Sciences Celebration 2017, which will be held Thursday, October 12 from 8:00 to 10:00 a.m. at the Historic Trenton Masonic Temple. 100 Barrack Street, Trenton.

HINJ’s 2017 honorees are: Continue reading

HINJ’s ‘Value of Medical Innovation’ Portal Showcases How Life Sciences Is Saving Money — And Lives

New Brunswick, NJ, July 9, 2017 ― The HealthCare Institute of New Jersey (HINJ) continues to update its Value of Medical Innovation, a fact-driven, consumer-friendly digital library that delves into the myriad benefits of research-driven medical innovation, which saves money — and saves lives.

Introduced in September 2015, HINJ’s Value of Medical Innovation presents statistics from a number of resources, including the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA), U.S. government sources and various medical research organizations. Continue reading

Opinion: Assemblyman Gary Schaer on Life Sciences, New Jersey and ‘A Blueprint for Tomorrow’

Asm. Gary Schaer

Trenton, NJ, July 3, 2017Assemblyman Gary S. Schaer (D-Passaic), Chair of the Assembly Budget Committee, in May shared the following with Innovation New Jersey readers:

Each time we tackle the state budget, we are reminded that it is a living, breathing document that, at its core, should fundamentally reflect our priorities.  As we enter final deliberations in crafting this year’s state budget, that reminder is all the more potent.

One of the reasons New Jersey’s economy lagged far behind most of the nation after the Great Recession is because we failed to make the proper investments to capitalize on our strengths and leverage our assets to grow our economy.  We cannot expect to move forward and grow as a state without planting the proper seeds.  Continue reading

Ex-Roche Campus Reinvented as ‘On3’ Science Center; Developer Seeks to Create Mini-Metropolis in the Suburbs’ for Life Sciences

Nutley, NJ, June 23, 2017 — Owen Proctor reports in The Record/NorthJersey.com that the former Hoffmann-La Roche campus that borders Clifton and Nutley has a new name.

“On3” seeks to incorporate living, working and playing in the Route 3 site, according to Prism Capital Partners’ principal Eugene Diaz. He described the redevelopment as “a mini-metropolis in the suburbs.”

The firm wants to reinvent the 116-acre campus that the pharmaceutical giant began vacating in 2012, creating a synergy among like-minded businesses geared toward life sciences. Continue reading

Opinion: Assemblyman Gary Schaer on ‘A Blueprint for Tomorrow’

Asm. Gary Schaer

Trenton, NJ, June 20, 2017Assemblyman Gary S. Schaer (D-Passaic), Chair of the Assembly Budget Committee, last month shared the following with Innovation New Jersey readers:

Each time we tackle the state budget, we are reminded that it is a living, breathing document that, at its core, should fundamentally reflect our priorities.  As we enter final deliberations in crafting this year’s state budget, that reminder is all the more potent.

One of the reasons New Jersey’s economy lagged far behind most of the nation after the Great Recession is because we failed to make the proper investments to capitalize on our strengths and leverage our assets to grow our economy.  We cannot expect to move forward and grow as a state without planting the proper seeds.  Continue reading

Opinion: Former Merck CEO and Princeton University President Emeritus on ‘Trump’s War on Science Threatens U.S. Prosperity’

Princeton, NJ, June 12, 2017Roy Vagelos, retired Chairman and CEO of Merck & Co. and Chairman of the Board of Regeneron Pharmaceuticals, and Shirley Tilghman, President Emeritus of Princeton University and a professor of Molecular Biology and Public Affairs, published the following opinion piece in The Star-Ledger on June 6:

In the past 40 years, the U.S. has been the world leader in converting fundamental scientific discoveries into innovative new treatments for life-threatening disease.  New drugs, vaccines, and medical devices have improved human health and increased our lifespan. Continue reading

HINJ to Serve as Lead Sponsor of Choose New Jersey’s Annual Reception at BIO International on June 19 in San Diego

New Brunswick, NJ, May 19, 2016 — The HealthCare Institute of New Jersey (HINJ) will serve, once again, as the lead sponsor of Choose New Jersey’s annual reception at BIO International Convention on Monday, June 19 from 5:00 to 7:00 p.m. at Top of the Hyatt at the Grand Hyatt San Diego.

Choose New Jersey will showcase top life sciences companies, universities, trade associations, the State government at its New Jersey Pavilion (Booth #1737) at BIO International 2017, which will be held from June 19 to 22 at the San Diego Convention Center. Continue reading

Biopharmaceutical Companies Unveil Latest GoBOLDLY TV Ad Showcasing ‘New World’ of Medicine

Washington, DC, May 17, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on May 15 unveiled its latest advertisement as part of its groundbreaking GOBOLDLY™ campaign, titled “New World, “featuring some of the most extraordinary breakthroughs in science being discovered by biopharmaceutical researchers.

“Biopharmaceutical researchers are driving unimaginable innovation in science, which is revolutionizing how the most complex diseases are treated,” said Stephen J. Ubl, president and chief executive officer of PhRMA.

“We truly are in a new world of medicine and on the verge of something even greater and more impactful. This promises a future with endless potential of scientific advances.” Continue reading